Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Jan 5, 2024
- Accession no.
- 0001209191-24-001084
- Filed
- Jan 5, 2024
- Trade date
- Jan 3, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 10 non-derivative transactions and 5 derivative transactions. Open-market sales total $530.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2024 | Class A Common Stock | CConversionAcquired | +10,000 | $0.00 | $0 | 801,328 | Direct | |
| Jan 3, 2024 | Class A Common Stock | GGiftDisposed | −10,000 | $0.00 | $0 | 791,328 | Direct | |
| Jan 3, 2024 | Class A Common Stock | MOption exerciseAcquired | +31,250 | $2.48 | +$77,500 | 822,578 | Direct | |
| Jan 3, 2024 | Class A Common Stock | SSaleDisposed | −30,853 | $9.49F3 | −$292,794.97 | 791,725 | Direct | |
| Jan 3, 2024 | Class A Common Stock | CConversionAcquired | +4,000 | $0.00 | $0 | 4,000 | Indirect | |
| Jan 3, 2024 | Class A Common Stock | SSaleDisposed | −4,000 | $9.51F6 | −$38,040 | 0 | Indirect | |
| Jan 3, 2024 | Class A Common Stock | CConversionAcquired | +20,000 | $0.00 | $0 | 20,000 | Indirect | |
| Jan 3, 2024 | Class A Common Stock | SSaleDisposed | −20,000 | $9.51F8 | −$190,200 | 0 | Indirect | |
| Jan 3, 2024 | Class A Common Stock | CConversionAcquired | +1,000 | $0.00 | $0 | 1,000 | Indirect | |
| Jan 3, 2024 | Class A Common Stock | SSaleDisposed | −1,000 | $9.49F10 | −$9,490 | 0 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 3, 2024 | Class A Common Stock | MOption exerciseDisposed | −31,250 | $0.00 | $0 | 375,000 | Direct | |
| Jan 3, 2024 | Class A Common Stock | CConversionDisposed | −10,000 | $0.00 | $0 | 6,481,496 | Direct | |
| Jan 3, 2024 | Class A Common Stock | CConversionDisposed | −4,000 | $0.00 | $0 | 515,000 | Indirect | |
| Jan 3, 2024 | Class A Common Stock | CConversionDisposed | −20,000 | $0.00 | $0 | 408,000 | Indirect | |
| Jan 3, 2024 | Class A Common Stock | CConversionDisposed | −1,000 | $0.00 | $0 | 118,875 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $9.26 to $9.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $9.27 to $9.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F8
This transaction was executed in multiple trades at prices ranging from $9.27 to $9.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F10
This transaction was executed in multiple trades at prices ranging from $9.29 to $9.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.